(VIANEWS) – Super Micro Computer (SMCI), Sotherly Hotels (SOHO), Heritage Insurance Holdings (HRTG) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Super Micro Computer (SMCI)
119.3% sales growth and 29.92% return on equity
Super Micro Computer, Inc., together with its subsidiaries, develops and manufactures high performance server and storage solutions based on modular and open architecture in the United States, Europe, Asia, and internationally. Its solutions range from complete server, storage systems, modular blade servers, blades, workstations, full racks, networking devices, server sub-systems, server management software, and security software. The company provides application-optimized server solutions, rackmount and blade servers, storage, and subsystems and accessories; and server software management solutions, such as Server Management Suite, including Supermicro Server Manager, Supermicro Power Management software, Supermicro Update Manager, SuperCloud Composer, and SuperDoctor 5. In addition, it offers server subsystems and accessories comprising server boards, chassis, power supplies, and other accessories. Further, the company provides server and storage system integration, configuration, and software upgrade and update services; and technical documentation services, as well as identifies service requirements, creates and executes project plans, and conducts verification testing and technical documentation, and training services. Additionally, it offers help desk and on-site product support services for its server and storage systems; and customer support services, including ongoing maintenance and technical support for its products. The company provides its products to enterprise data centers, cloud computing, artificial intelligence, and 5G and edge computing markets. It sells its products through direct and indirect sales force, distributors, value-added resellers, system integrators, and original equipment manufacturers. The company was incorporated in 1993 and is headquartered in San Jose, California.
Earnings Per Share
As for profitability, Super Micro Computer has a trailing twelve months EPS of $12.74.
PE Ratio
Super Micro Computer has a trailing twelve months price to earnings ratio of 68.62. Meaning, the purchaser of the share is investing $68.62 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.92%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Super Micro Computer’s EBITDA is 76.26.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 249.7% and 101.4%, respectively.
Yearly Top and Bottom Value
Super Micro Computer’s stock is valued at $874.26 at 10:22 EST, way above its 52-week high of $606.00.
Volume
Today’s last reported volume for Super Micro Computer is 5130970 which is 17.47% below its average volume of 6217820.
Previous days news about Super Micro Computer(SMCI)
- Zacks.com featured highlights super micro computer, w.w. grainger, casey's and alliancebernstein. According to Zacks on Monday, 12 February, "Chicago, IL - February 12, 2024 - Stocks in this week’s article are Super Micro Computer (SMCI Quick QuoteSMCI – Free Report) , W.W. Grainger (GWW Quick QuoteGWW – Free Report) , Casey’s General Stores (CASY Quick QuoteCASY – Free Report) and AllianceBernstein (AB Quick QuoteAB – Free Report) ."
- According to Zacks on Monday, 12 February, "These factors are favorable for prominent industry players like Super Micro Computer (SMCI Quick QuoteSMCI – Free Report) , NetApp (NTAP Quick QuoteNTAP – Free Report) , Western Digital (WDC Quick QuoteWDC – Free Report) and Pure Storage (PSTG Quick QuotePSTG – Free Report) . "
2. Sotherly Hotels (SOHO)
14.4% sales growth and 20.21% return on equity
Sotherly Hotels Inc. is a self-managed and self-administered lodging REIT focused on the acquisition, renovation, upbranding and repositioning of upscale to upper-upscale full-service hotels in the Southern United States. Currently, the Company's portfolio consists of investments in twelve hotel properties, comprising 3,156 rooms, as well as interests in two condominium hotels and their associated rental programs. The Company owns hotels that operate under the Hilton Worldwide, Hyatt Hotels Corporation, and Marriott International, Inc. brands, as well as independent hotels. Sotherly Hotels Inc. was organized in 2004 and is headquartered in Williamsburg, Virginia.
Earnings Per Share
As for profitability, Sotherly Hotels has a trailing twelve months EPS of $0.08.
PE Ratio
Sotherly Hotels has a trailing twelve months price to earnings ratio of 17.12. Meaning, the purchaser of the share is investing $17.12 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.21%.
Volume
Today’s last reported volume for Sotherly Hotels is 5772 which is 91.58% below its average volume of 68588.
Sales Growth
Sotherly Hotels’s sales growth is 37.2% for the current quarter and 14.4% for the next.
3. Heritage Insurance Holdings (HRTG)
14.3% sales growth and 19.97% return on equity
Heritage Insurance Holdings, Inc., through its subsidiaries, provides personal and commercial residential insurance products. The company offers personal residential property insurance for single-family homeowners and condominium owners, and rental property insurance in the states of Alabama, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Maryland, Massachusetts, Mississippi, New Jersey, New York, North Carolina, Rhode Island, South Carolina, and Virginia; commercial residential insurance for properties in Florida, New Jersey, and New York; and licensed in the state of Pennsylvania, as well as personal residential and wind-only property insurance. It also provides restoration, and emergency and recovery services; and property management, and reinsurance services. The company writes personal line policies through a network of retail independent agents, wholesale agents, and a partnership with a direct agency, as well as indirectly to approximately 1,500 retail locations through eight wholesale agency relationships; and personal and commercial insurance policies through a network of approximately 70 independent agencies. Heritage Insurance Holdings, Inc. was founded in 2012 and is headquartered in Tampa, Florida.
Earnings Per Share
As for profitability, Heritage Insurance Holdings has a trailing twelve months EPS of $0.98.
PE Ratio
Heritage Insurance Holdings has a trailing twelve months price to earnings ratio of 5.93. Meaning, the purchaser of the share is investing $5.93 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.97%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 4.2% and positive 9.1% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12.6%, now sitting on 723.12M for the twelve trailing months.
4. STAAR Surgical Company (STAA)
13.4% sales growth and 5.57% return on equity
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Earnings Per Share
As for profitability, STAAR Surgical Company has a trailing twelve months EPS of $0.38.
PE Ratio
STAAR Surgical Company has a trailing twelve months price to earnings ratio of 73.34. Meaning, the purchaser of the share is investing $73.34 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.57%.
Yearly Top and Bottom Value
STAAR Surgical Company’s stock is valued at $27.87 at 10:22 EST, way under its 52-week high of $79.43 and higher than its 52-week low of $27.00.
5. Lantheus Holdings (LNTH)
11.6% sales growth and 15.57% return on equity
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent. The company also offers AZEDRA, a radiotherapeutic therapy; Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; PNT2002 for pre-chemotherapy patients; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; and PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer. The company serves hospitals, independent diagnostic testing facilities, government facilities, integrated delivery networks, radiopharmacies, clinics, distirbutors, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; and FUJIFILM. The company was founded in 1956 and is based in Bedford, Massachusetts.
Earnings Per Share
As for profitability, Lantheus Holdings has a trailing twelve months EPS of $1.5.
PE Ratio
Lantheus Holdings has a trailing twelve months price to earnings ratio of 36.66. Meaning, the purchaser of the share is investing $36.66 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.57%.
6. American Water Works (AWK)
8.8% sales growth and 10.42% return on equity
American Water Works Company, Inc., through its subsidiaries, provides water and wastewater services in the United States. It offers water and wastewater services to approximately 1,600 communities in 14 states serving approximately 3.4 million active customers. The company serves residential customers; commercial customers, including food and beverage providers, commercial property developers and proprietors, and energy suppliers; fire service and private fire customers; industrial customers, such as large-scale manufacturers, mining, and production operations; public authorities comprising government buildings and other public sector facilities, such as schools and universities; and other utilities and community water and wastewater systems. It also provides water and wastewater services on various military installations; and undertakes contracts with municipal customers, primarily to operate and manage water and wastewater facilities, as well as offers other related services. In addition, the company operates approximately 80 surface water treatment plants; 490 groundwater treatment plants; 175 wastewater treatment plants; 53,500 miles of transmission, distribution, and collection mains and pipes; 1,100 groundwater wells; 1,700 water and wastewater pumping stations; 1,100 treated water storage facilities; and 73 dams. It serves approximately 14 million people with drinking water, wastewater, and other related services in 24 states. The company was founded in 1886 and is headquartered in Camden, New Jersey.
Earnings Per Share
As for profitability, American Water Works has a trailing twelve months EPS of $4.84.
PE Ratio
American Water Works has a trailing twelve months price to earnings ratio of 24.81. Meaning, the purchaser of the share is investing $24.81 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.42%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Feb 6, 2024, the estimated forward annual dividend rate is 2.83 and the estimated forward annual dividend yield is 2.29%.
Moving Average
American Water Works’s worth is under its 50-day moving average of $130.22 and way under its 200-day moving average of $135.91.
Sales Growth
American Water Works’s sales growth is 9.5% for the current quarter and 8.8% for the next.
7. Ryanair Holdings (RYAAY)
8% sales growth and 28.82% return on equity
Ryanair Holdings plc, together with its subsidiaries, provides scheduled-passenger airline services in Ireland, the United Kingdom, Italy, Spain, and internationally. It is also involved in the provision of various ancillary services, such as non-flight scheduled and Internet-related services, as well as in-flight sale of beverages, food, duty-free, and merchandise; and markets car hire, travel insurance, and accommodation services through its website and mobile app. In addition, the company offers aircraft and passenger handling, ticketing, and maintenance and repair services; and markets car parking, fast-track, airport transfers, attractions, and activities on its website and mobile app, as well as sells gift vouchers. Ryanair Holdings plc was incorporated in 1996 and is headquartered in Swords, Ireland.
Earnings Per Share
As for profitability, Ryanair Holdings has a trailing twelve months EPS of $9.62.
PE Ratio
Ryanair Holdings has a trailing twelve months price to earnings ratio of 14.28. Meaning, the purchaser of the share is investing $14.28 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.82%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 16.7%, now sitting on 13.12B for the twelve trailing months.
8. Incyte Corporation (INCY)
6.4% sales growth and 9.28% return on equity
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Earnings Per Share
As for profitability, Incyte Corporation has a trailing twelve months EPS of $1.88.
PE Ratio
Incyte Corporation has a trailing twelve months price to earnings ratio of 31.55. Meaning, the purchaser of the share is investing $31.55 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.28%.
Previous days news about Incyte Corporation(INCY)
- According to Zacks on Monday, 12 February, "Let’s see how things have shaped up for Biogen Inc. (BIIB Quick QuoteBIIB – Free Report) , Zoetis Inc. (ZTS Quick QuoteZTS – Free Report) and Incyte Corporation (INCY Quick QuoteINCY – Free Report) ahead of their fourth-quarter 2023 results. "
